Browsing Tag
NLRP3
4 posts
Why industry observers are watching Tenvie Therapeutics’ TNV262 biomarker readout in 2026
Tenvie Therapeutics’ TNV262 readout in 2026 could reshape obesity and cardiometabolic drug development. Read why markets are watching closely.
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field.
Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?
Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.